The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Please bear with me here...
Looking at slides from the Avacta Investor Meet Company presentation, on September 28th, slide 26, on the LFT says:
* Clear focus by authorities on frequent testing to identify infectious people
* High specificity is essential to avoid very large numbers of false positives being referred for follow up.
* Sensitivity must be high (>90%) within the infectious group.
Not really as helpful as one might like, but an intention to do better than Sona Nanotech.
So how did Cytiva have Sona S&S on the lab at 96% and 96%, but clinical trials showed a marked degradation in Sensitivity to 84.6%.
That's some variance!
We also know that the LFT is prone to accuracy variation (I assume bad sensitivity as specificity should be highly constant) due to production variations. This was reported by an ex-Avacta employee on the Avacta BB.
Did Cytiva have a sensitivity systematic measurement error in their assessment of the Sona and Avacta LFTs?
Who knows?
Dido is reportly not keen on using saliva for testing. Why? LAMP and NCYT are moving to saliva.
Are the Government having second thoughts with Moonshot and the Avacta LFT?
Heaven forbid! But I need to ask the question.
The country cannot afford anither lockdown.
It could not afford school meals!
Vaccine may be close.
Could the Government contemplate proceding with LAMP, PCR and other novel tests and dismiss the cost of the LFT (because it is to late)?
I wonder .....
What does this mean for Carl's test??
Clinical testing seems to be the relevant thing for use of the test assay not lab testing.
It would be useful to know how the two moderately different sets of figures can be reconciled.
I was circumspect about Avacta's LFT sensitivity. This circumspection has increased!
Is Avacta's sensitivity good enough for FDA approval or have Cytiva dropped the ball??
Carl's test is fast, sensitive and the aptamer synthetic chimeric protein "soup" makes it specific.
Moreover, this technology offers the possibility of quantification of the target sequences (see poster HaHa posts)
I really do wonder if Carl's test is THE Antigen test.
I really do wish the Government would throw everything at this test to validate its S&S...
Perhaps I am wrong. But if I am right. WoW!
I keep asking why has the Avacta LFT been delayed to Q1 21?? ....
Well with the Market Cap so low here, there is a lot of scope for share growth from covid killer face masks and textiles and from Carl's test.
No one supplier can supply all of the covid tests required.
What value would we now put on BRH shares with two fantastic (amongst others) Companies in the BRH portfolio?
GLA.
DYOR.
Carl's test - fast (tick), sensitive (tick), specific (tick)
Test, test, test
Oh yes I hope so, from what I have read it would seem Carl,s test is the most thorough and the quickest too, I think BRH will be very interesting by next February or March. What do you think
They still need to complete the clinical tests to see the final results - no matter how long they have been in this business - it's all down to clinical testing results - so it's not a given on a 100% basis
Lab results are different to clinical settings. However, Carl seems extremely confident this test will pass through. I trust he is right given his credentials.
Like everything in life, there is no guarantee anyone will get approvals, that includes Avacta, Genedrive,etc,etc...
Be patient because we'll be valued on those forementioned soon.
Haha..
So Sona Nanotech which had S&S independently verified in the lab at Sensitivity 96% and Specificity 96%
https://sonanano.com/sona-nanotech-updates-on-timing-of-clinical-in-field-validation-studies-for-its-covid-19-antigen-test/
and during clinical verification COVID-19 antigen test achieved a sensitivity of 84.6% and a specificity of 90.0% in a study across 99 collected clinical patient samples
https://sonanano.com/sona-nanotech-announces-clinical-evaluation-study-results-for-its-covid-19-antigen-test/
cannot get FDA approval. WoW!
Now I really do wonder what Avacta's affimer LFT sensitivity is!!! Is it good enough? Or is a fast complementary test required for LFT rollout?
Or is Carl's test the ONLY antigen MHRA Guidelines Desired Criterion mass test solution?
Time will tell. Time will tell!
DYOR.
Carl's test - fast (tick), sensitive (tick), specific (tick)
Test, test, test
Halifax, Nova Scotia--(Newsfile Corp. - October 29, 2020) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company"), a developer of rapid, point-of-care diagnostic tests, received notice from the FDA that the Company's request for an emergency use authorization ("EUA") for the marketing of its rapid COVID-19 antigen test in the United States "is not a priority" and consequently such authorization will not be issued at this time. The FDA cited current EUA request prioritization criteria as including "the public health need for the product" and did not comment on the performance of the Sona test.
Health Canada continues its evaluation of the Company's application for an Interim Order ("IO") authorization for its test as a 'point-of-care' medical diagnostic device. The Company yesterday received additional questions on its application. Also, Health Canada has submitted the Company's tests to the Public Health Agency of Canada's National Microbiology Laboratory for evaluation, which is ongoing.
Sona has already sold tests to Canadian companies under 'research use only' labelling. These tests are being evaluated as a screening tool for the identification of COVID-19 amongst employees. Potential programs envision having employees that test positive with the Sona rapid test designated 'presumed positive', removed from congested work environments and referred to medical professionals for confirmatory testing. This process would allow employers to remove affected staff from the work place, reduce potential spread and help businesses remain open in pandemic conditions. The Company believes that screening individuals in congested environments, whether they be mining operations, airports or long-term care facilities is the best use case for Sona's rapid test and that this added testing tool can play an important role in Canada's response to Covid-19. These tests were manufactured in the Company's in-house manufacturing facility.
The Company continues its manufacturing scale-up activities, having run multiple pilot production batches with a contract manufacturing organization, and is in advanced discussions with other manufacturers. The Company expects to be in a position to ship commercial tests to customers in November, subject to regulatory approval.
Sona still worth $200m. The lengthy delay in FDA EUA approval time for Sona was the writing on the wall really.
Paraytec will show the world how a test is really done..